Doctor of Philosophy, The Ohio State University, 2024, Medical Science
Ewing sarcoma is a highly aggressive tumor of bone and muscle tissues, primar-
ily affecting children, adolescent, and young adults. While the clinical outcome for
patients with localized Ewing sarcoma have improved due to a combination of ap-
proaches including surgery, radiation, and a high-dose chemotherapies, the same can not be said for patients with metastatic and relapsed diseases. The standard treatment regimen has seen little innovation over the past decades. This stagnation in therapeutic advancement reflects a critical gap in our knowledge, which, if addressed, could pave the way for more targeted interventions for Ewing sarcoma patients.
Central to Ewing sarcoma pathogenesis is the EWS::FLI fusion oncoprotein. This
fusion results from a translocation between chromosomes 11 and 22, merging the
EWSR1 and FLI1 genes. EWS::FLI is an aberant transcription factor that dysregu-
lates the gene expression profile of normal cells, leading to their malignant transfor-
mation. The fusion of the EWS domain with the FLI domain endows the final protein
a novel ability to bind at GGAA microsatellites, which are scattered across the hu-
man genome in great numbers and with varied characteristics. EWS::FLI reprograms the epigenetic landscape by binding at GGAA repeats, opening nucleosome-wrapped DNA, recruiting chromatin modifiers, and altering chromatin architecture and the enhancer landscape.
We investigated the role of the DBD-α4 helix in the FLI domain of the fusion
protein in genome regulation. Employing a mutli-omics approach, we delineated the
mechanisms by which this alpha-helix participates in the transcriptional activation
capacity of EWS::FLI. Our studies unveiled that the DBD-α4 helix is required for col-
lective binding at long and dense GGAA microsatellites, a process integral to various
forms of genome regulation by EWS::FLI including formation of topologically asso-
ciated domains (TADs), short-range loops, Ewing-specific enhancers, and pr (open full item for complete abstract)
Committee: Emily Theisen (Advisor)
Subjects: Medicine; Oncology